



# VENMAX

DRUGS AND PHARMACEUTICALS LIMITED.

---

To,  
BSE Limited,  
Phiroze Jeejeebhoy,  
Towers, Dalal Street,  
Fort, Mumbai - 400 001.

Date: 15.05.2023

**Scrip code: 531015**

Dear Sir/Madam,

**Sub: Audited Financial Results for the Quarter and year ended 31<sup>st</sup> March, 2023:**

Pursuant to Reg.30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held on 15<sup>th</sup> May, 2023 had inter-alia,

- (i) Approved the Audited Financial Results of the Company for the quarter (Q4) and Year ended 31<sup>st</sup> March, 2023 and Auditors Report thereon.


This is for your information and record.

Thanking you,

Yours Faithfully,

For Venmax Drugs and Pharmaceuticals Limited

  
N. Krishnaiah  
Director  
DIN:07279009



M/s VENMAX DRUGS AND PHARMACEUTICALS LIMITED  
 Shed No.22, Plot No.84, Phase-1, IDA, Cherlapally, Hyderabad, Kangareddy, Telangana, Pincode-500055  
 (CIN: L24230TG1988PLC009102)

Extract of Audited financial results for the Quarter and Year Ended 31st March, 2023.

S.No	Particulars	Quarter ended			
		March,31st 2023	Dec. 31st 2022	March,31st 2022	Year ended 31.03.2022
1	Total Income	26.93	5.00	198.30	198.30
2	Net Profit (before Tax, Exceptional and/or Extraordinary items)	19.22	1.76	194.89	184.66
3	Net Profit before tax (after Exceptional and/or Extraordinary items)	19.22	1.76	194.89	184.66
4	Net Profit after tax (after Exceptional and/or Extraordinary items)	19.27	1.81	194.88	184.62
5	Total Comprehensive Income [Comprising Profit after tax and Other Comprehensive Income (after tax)]	19.27	1.81	194.88	184.62
6	Paid up Equity Share Capital (Rs.10/- Per Equity Share)	523.89	523.89	523.89	523.89
7	Reserves (excluding Revaluation Reserve) as shown in the Balance Sheet of previous year ended				(617.90)
8	Earnings Per Share (of Rs.10/- each) (Not Annualised):				
	a) Basic	0.37	0.03	3.72	3.52
	b) Diluted	0.37	0.03	3.72	3.52

The above Financial results as recommended by the Audit Committee were considered and approved by the Board of Directors at their meeting held on 15/05/2023

Note: The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchange under Regulations 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on company's website and the stock exchange's website www.bseindia.com.

By and on behalf of the board  
 For Venmax Drugs and Pharmaceuticals Limited



N. Krishnaiah  
 Director  
 DIN: 07279009

Date: 15/05/2023  
 Place: Hyderabad

**M/s. VENMAX DRUGS AND PHARMACEUTICALS LIMITED**  
 Shed No.22, Plot No.84, Phase-1, IDA, Cherlagully, Hyderabad, Rangareddy, Telangana, Pincode-500055  
 (CIN: L24230TG1988PLC009102)

**Audited Financial Results for the Quarter and Year Ended 31st, March 2023**

S No	Particulars	Quarter Ended			Year Ended	
		March ,31st 2023	Dec. 31st 2022	March ,31st 2022	March 31st, 2023	March 31st, 2022
		Audited	Un Audited	Audited	Audited	Audited
1	<b>Income</b>					
	a) Revenue from Operations	-	-	-	-	-
	b) Other Income	26.93	5.00	198.30	41.93	198.30
	<b>Total Income</b>	<b>26.93</b>	<b>5.00</b>	<b>198.30</b>	<b>41.93</b>	<b>198.30</b>
2	<b>Expenses</b>					
	a) Cost of materials Consumed	-	-	-	-	-
	b) Changes in inventories	-	-	-	-	-
	c) Employee benefits expense	0.73	1.01	0.30	3.02	1.20
	d) Finance costs	-	-	-	-	-
	e) Depreciation and amortization expenses	0.20	0.20	0.23	0.80	0.91
	f) Other expenses	6.78	2.028	2.88	15.53	11.53
	<b>Total Expenses (a to f)</b>	<b>7.71</b>	<b>3.24</b>	<b>3.41</b>	<b>19.36</b>	<b>13.65</b>
3	<b>Profit before tax (1-2)</b>	<b>19.22</b>	<b>1.76</b>	<b>194.89</b>	<b>22.57</b>	<b>184.66</b>
4	<b>Tax expenses</b>					
	- Income Tax	-	-	-	-	-
	- Deferred Tax	(0.05)	(0.05)	0.01	0.01	0.03
5	<b>Net Profit for the period (3-4)</b>	<b>19.27</b>	<b>1.81</b>	<b>194.88</b>	<b>22.56</b>	<b>184.62</b>
6	<b>Other comprehensive income</b>					
	a) (i) Items that will not be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
	b) (i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	<b>Total other comprehensive income</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
7	<b>Total Comprehensive income (5 +6)</b>	<b>19.27</b>	<b>1.81</b>	<b>194.88</b>	<b>22.56</b>	<b>184.62</b>
8	<b>Paid-up Equity Share Capital</b> (Rs. 10/- per Equity Share)	523.89	523.89	523.89	523.89	523.89
9	<b>Other Equity</b>	-	-	-	(595.34)	(617.90)
10	<b>Earnings per share</b> (Face Value of Rs. 10/- each)					
	(a) Basic (In Rs.)	0.37	0.03	3.72	0.43	3.52
	(b) Diluted (In Rs.)	0.37	0.03	3.72	0.43	3.52

1 These financial results have been prepared in accordance with Indian Accounting Standards (Ind- AS) as prescribed under section 133 of Companies Act 2013 (Indian Accounting Standards) Rules 2015 as amended by the companies(Indian Accounting standards) (amendment) rules 2016.

2 The above Financial results as recommended by the Audit Committee were considered and approved by the Board of Directors at their meeting held on 15-05-2023.

3 The Financial results are reviewed by the statutory auditor's as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015.

4 The full format of the Quarterly Financial Results are available on company's website and the stock exchange's website www.bseindia.com.

5 Previous year/period figures have been regrouped, wherever necessary, inline with the current period/year presentation.

6 The entire operations of the company relates to only one segment. Hence, segment reporting as per IND AS-108 is not applicable.

Place: Hyderabad  
Date: 15/05/2023

By and on behalf of the board  
For Venmax Drugs and Pharmaceuticals Limited

*N. Krishnaiah*  
Nooka Krishnaiah  
Director  
DIN: 07279009



**M/s. VENMAX DRUGS AND PHARMACEUTICALS LIMITED**  
**Shed No.22, Plot No.84, Phase-I, IDA, Cherlapally, Hyderabad, Rangareddy, Telangana, Pincode-500055**  
**(CIN: L24230TG1988PLC009102)**  
**STATEMENT OF ASSETS AND LIABILITIES**

(Rs. In Lakhs)

Particulars	As at 31.03.2023	As at 31.03.2022
<b>ASSETS</b>		
<b>Non-Current Assets</b>		
Property, Plant and Equipment	5.00	5.56
Other Intangible Assets	2.30	2.55
Financial Assets;		
- Investments	-	-
- Other financial assets	-	-
Deferred Tax Assets (Net)	-	-
Other non-current assets	-	-
	<b>7.30</b>	<b>8.11</b>
<b>Current Assets</b>		
Inventories	-	-
Financial Assets;		
- Investments	-	-
- Trade Receivables	3.64	3.64
- Cash and cash Equivalents	0.02	0.02
- Bank balances other than cash and cash equivalents	0.01	0.01
Current Tax Assets (Net)	-	-
Other current assets	10.17	9.58
	<b>13.84</b>	<b>13.25</b>
<b>TOTAL ASSETS</b>	<b>21.14</b>	<b>21.36</b>
<b>EQUITY AND LIABILITIES</b>		
Equity		
Equity Share Capital	523.89	523.89
Other Equity	(595.34)	(617.90)
<b>Total Equity</b>	<b>(71.44)</b>	<b>(94.01)</b>
<b>LIABILITIES</b>		
<b>Non-Current Liabilities</b>		
Financial Liabilities		
- Borrowings	-	-
Provisions	-	-
Deferred Tax Liabilities (Net)	0.47	0.46
	<b>0.47</b>	<b>0.46</b>
<b>Current Liabilities</b>		
Financial Liabilities		
- Borrowings	35.21	34.90
- Trade Payables		
(A) total outstanding dues of micro enterprises and small enterprises; and	-	-
(B) total outstanding dues of creditors other than micro enterprises and small enterprises	32.85	47.06
- Other Financial Liabilities	15.31	24.20
Current Tax Liabilities (Net)	-	-
Provisions	1.18	1.18
Other current liabilities	7.57	7.57
	<b>92.13</b>	<b>114.91</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>21.14</b>	<b>21.36</b>



**M/s. VENMAX DRUGS AND PHARMACEUTICALS LIMITED**  
 Shed No.22, Plot No.84, Phase-1, IDA, Cherlapally, Hyderabad, Rangareddy, Telangana, Pincode-500055  
 (CIN: L24230TG1988PLC009102)

**Cash Flow Statement For The period Ended 31st March, 2023**

(Rs. In Lakhs)

PARTICULARS	Year ended Mar 31, 2023	Year ended Mar 31, 2022
	Audited	Audited
<b>A) CASH FLOW FROM OPERATING ACTIVITIES</b>		
Net Profit as per Profit & Loss A/c	22.57	184.66
Adjustment for :		
Depreciation	0.80	0.91
Other comprehensive income	-	-
<b>Net Operating Profit Before Working Capital</b>	<b>23.38</b>	<b>185.57</b>
Changes		
Adjustment for :		
Trade & Other Receivables	-	(0.01)
Changes in inventory	-	-
Other Current Assets	(0.59)	1.00
Trade Payables	(14.21)	0.59
Other Financial liabilities	(8.89)	4.68
Other current liabilities	-	1.80
Provisions	-	(3.11)
<b>Net Cash from Operating Activities</b>	<b>(0.31)</b>	<b>190.51</b>
Direct taxes paid	-	-
<b>Net Cash from Operating Activities</b>	<b>(0.31)</b>	<b>190.51</b>
<b>B) CASH FLOW FROM INVESTING ACTIVITIES</b>		
Purchase of Fixed Assets	-	-
<b>Net Cash from Investing Activities</b>	<b>-</b>	<b>-</b>
<b>C) CASH FLOW FROM FINANCING ACTIVITIES</b>		
From Bank Borrowings		
Proceeds from long/short term borrowings	0.31	(198.00)
<b>Net Cash from Financing Activities</b>	<b>0.31</b>	<b>(198.00)</b>
Net Increase in Cash & Cash Equivalents	-	(7.49)
Add : Opening Cash & Cash Equivalents	0.03	7.53
<b>Cash and Cash equivalents at the end of the year</b>	<b>0.03</b>	<b>0.03</b>
<b>1) Cash and Cash equivalents includes:</b>		
Particulars	Year ended Mar 31, 2023	Year ended Mar 31, 2022
Cash on hand	0.02	0.02
<b>Cash Equivalents:</b>		
Current Accounts	0.01	0.01
<b>Total</b>	<b>0.03</b>	<b>0.03</b>





# VENMAX

DRUGS AND PHARMACEUTICALS LIMITED.

---

Date: 15.05.2023

To,  
BSE Limited,  
Phiroze Jeejeebhoy,  
Towers, Dalal Street,  
Fort, Mumbai - 400001.

Scrip code: 531015

Dear Sir/Madam,


**Sub:** Declaration pursuant to regulation 33 (3) (d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

I, N. Krishnaiah, Director of Venmax Drugs and Pharmaceuticals Limited hereby declare that, the statutory Auditors of the company, M/s. NSVR & Associates LLP, Chartered Accountants have issued an Audit Report with unmodified/unqualified opinion on Audited Financial Results of the company for the quarter and year ended 31<sup>st</sup> March, 2023.

This declaration is issued in compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Yours faithfully,

For Venmax Drugs and Pharmaceuticals Limited

  
N. Krishnaiah  
Director  
DIN:07279009





**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF QUARTERLY AND ANNUAL  
FINANCIAL RESULTS**

**TO,  
THE BOARD OF DIRECTORS,  
M/s. VENMAX DRUGS AND PHARMACEUTICALS LIMITED.**

**Opinion**

We have audited the accompanying quarterly financial results of **M/s. VENMAX DRUGS AND PHARMACEUTICALS LIMITED** (the company) for the quarter ended 31<sup>st</sup> March, 2023 and the year to date results for the period from 1<sup>st</sup> April, 2022 to 31<sup>st</sup> March, 2023, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these financial results:

- (i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- (ii) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter ended 31<sup>st</sup> March, 2023 and the year to date results for the period from 1<sup>st</sup> April, 2022 to 31<sup>st</sup> March, 2023.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the financial results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Management's Responsibilities for the financial results**

These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors is responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

**Auditor's Responsibilities for the Audit of the financial results for the quarter and year ended 31<sup>st</sup> March, 2023**

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:



- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results of the company to express an opinion on the financial results.

Materiality is the magnitude of misstatements in the Statement that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Statement may be influenced. We consider quantitative materiality and qualitative factors:

- (i) In planning the scope of our audit work and in evaluating the results of our work and
- (ii) To evaluate the effect of any identified misstatements in the Statement.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**Other Matters**

The statement includes the results for the quarter ended March 31, 2023 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2023 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under Listing Regulations.  
Our opinion on the statement is not modified in respect of this matter.

**For NSVR & ASSOCIATES LLP**

Chartered Accountants

FRN: 008801S/S200060

SURESH     Digitally signed by  
GANNAMA     SURESH  
                   GANNAMANI  
NI                 Date: 2023.05.15  
                         16:47:11 +05'30'

**Suresh Gannamani**

Partner

M. No: 226870

UDIN: 23226870BGVRZP2980



Place: Hyderabad

Date: 15/05/2023.